In a report released today, Lawrence Keusch from Raymond James maintained a Buy rating on Stryker (SYK). The company’s shares closed last Tuesday at $239.66, close to its 52-week high of $245.34.
According to TipRanks.com, Keusch is a 4-star analyst with an average return of 9.1% and a 72.0% success rate. Keusch covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Intuitive Surgical.
Stryker has an analyst consensus of Moderate Buy, with a price target consensus of $243.45, which is a 1.7% upside from current levels. In a report issued on December 30, BTIG also assigned a Buy rating to the stock with a $252.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $245.34 and a one-year low of $124.54. Currently, Stryker has an average volume of 1.03M.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stryker Corp. engages in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The Medsurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling, and reprocessed medical devices. The Neurotechnology and Spine segment pertains to spinal implants and neurovascular products. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.
